Printer Friendly

Caris' tumour profiling service successfully guides anticancer therapy of patient with neuroendocrine carcinoma.

M2 PHARMA-August 5, 2014-Caris' tumour profiling service successfully guides anticancer therapy of patient with neuroendocrine carcinoma

(C)2014 M2 COMMUNICATIONS

5 August 2014 - US personalised medicine specialist Caris Life Sciences unveiled Tuesday data from a case study showing that its Caris Molecular Intelligence tumour profiling service helped guide successful therapy with both a kinesin 11 (KIF11) inhibitor and imatinib for a patient with neuroendocrine carcinoma with an activating KIT mutation.

The study, featured in the Journal of the National Comprehensive Cancer Network (JNCCN), demonstrated the first documented case of an activating KIT mutation in a neuroendocrine tumour (NET) and of successful therapy with both a KIF11 inhibitor and imatinib. The patient, a 48-year-old man, had a refractory, metastatic NET and was unresponsive to conventional chemotherapy. The patient received a KIF11 inhibitor in a Phase I study and had a clinically meaningful partial response, but following 20 months, he had tumour progression.

Immunohistochemistry (IHC) analysis performed through Caris Molecular Intelligence showed an activating mutation in exon 11 of the KIT receptor tyrosine kinase, which has been related to response to imatinib in patients with gastrointestinal stromal tumours (GIST). Following two weeks of treatment with imatinib, the patient's pain was relieved and the presence of disease significantly declined. Following a two-month therapy, the patient's recurrent hepatomegaly had normalised, and a liver CT scan affirmed a significant decrease of hepatic lesions. A total of 46 months following the initial diagnosis, the patient had received imatinib for 12 months with good tolerability and no signs of cancer in radiographic imaging.

In this case, use of multi-platform molecular profiling validated the potential benefit of imatinib, which resulted in notable symptomatic and radiographic improvements for the patient. These findings additionally back the method of molecular characterisation of individual tumours to improve anticancer therapy, commented study co-investigator Dr. Igor Astsaturov, medical oncologist at Fox Chase Cancer Center in Philadelphia.

Caris Molecular Intelligence uses various analytical technologies, such as immunohistochemistries, fluorescence and chromogenic in situ hybridisation, polymerase chain reaction and next-generation sequencing, to provide full and clinically relevant profile of a person's unique cancer-related biomarkers. The product also evaluates another biological components including RNA and protein expression levels to help doctors choose the most appropriate therapy for each patient.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2014 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2014 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Aug 5, 2014
Words:382
Previous Article:Regulus, Biogen Idec team up to find microRNA biomarkers for multiple sclerosis.
Next Article:Proteomics International validates biomarkers as part of CDx test development.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters